SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, conix, Phaeton, $Pistol Pete$
Search This Board:
Last Post: 10/24/2016 10:39:27 PM - Followers: 353 - Board type: Free - Posts Today: 0


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Current Report Filing (8-k) 09/22/2016 08:02:07 AM
MNKD News: MannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global Investment Conference 09/02/2016 05:00:00 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/31/2016 05:38:18 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/31/2016 05:37:18 PM
MNKD News: Securities Registration: Employee Benefit Plan (s-8) 08/29/2016 04:31:55 PM
#19634  Sticky Note $MNKD MannKind Is 'Making Progress' On Its Alternative $Pistol Pete$ 08/30/16 04:46:19 PM
#19516  Sticky Note Nice blog article on MannKind. Phaeton 08/20/16 02:25:50 PM
#19895     JOHN SEBASTIAN BIVONA WHS 10/24/16 10:39:27 PM
#19894   Vdex Diabetes of Canoga Park WHS 10/24/16 10:31:50 PM
#19893   * * $MNKD Video Chart 10-24-16 * * ClayTrader 10/24/16 04:31:47 PM
#19892   MNKD 5 20 50 200 SMA TREND1 10/24/16 01:46:09 PM
#19891   CT_Investor FROM SA TREND1 10/22/16 01:15:04 PM
#19890   Thank you for all of your continued interest WHS 10/22/16 07:03:32 AM
#19889   risingskepticism FROM SA TREND1 10/21/16 11:44:59 PM
#19888   * * $MNKD Video Chart 10-21-16 * * ClayTrader 10/21/16 04:33:34 PM
#19887   spotted it scanning... Chance 10/21/16 04:09:16 PM
#19886   10/14/16 risingskepticism FROM SA TREND1 10/21/16 12:31:22 PM
#19885   It's clearly a pump and dump dmcc2087 10/21/16 11:12:41 AM
#19884   bulls running Chance 10/21/16 09:49:46 AM
#19883   back to over 1$ coming. afrezza works an harry crumb 10/20/16 09:09:24 PM
#19880   * * $MNKD Video Chart 10-20-16 * * ClayTrader 10/20/16 04:23:17 PM
#19879   closed above the 20day/average... Chance 10/20/16 04:07:16 PM
#19878   got some low50s riding high as it goes... Chance 10/20/16 03:13:52 PM
#19877   MNKD is going BK soon IMHO. TREND1 10/19/16 11:00:02 PM
#19876   SNY peak scripts were 600 plus. TREND1 10/18/16 12:42:51 PM
#19875   risingskepticism TREND1 10/17/16 06:16:47 PM
#19874   * * $MNKD Video Chart 10-17-16 * * ClayTrader 10/17/16 05:19:28 PM
#19873   10/14/16 TREND1 10/17/16 12:38:35 PM
#19872   Fun to watch Hedge funds run another great kugel 10/17/16 10:49:35 AM
#19871   You should of listened to grandma....She was right TREND1 10/16/16 10:39:47 PM
#19870   Waste of my time .Thanks tyfoidhana 10/16/16 09:49:35 PM
#19868   And the point to this post is? And tyfoidhana 10/16/16 06:10:52 PM
#19867   $MNKD mc67 10/16/16 04:26:25 PM
#19866   If the 1059 doctor is only a week WHS 10/16/16 09:04:30 AM
#19865   Said the management can not WHS 10/16/16 08:54:36 AM
#19864   south dakota: 1 WHS 10/16/16 08:38:05 AM
#19863   maine: 3 WHS 10/16/16 08:06:58 AM
#19862 Looking to find a doctor who can prescri WHS 10/16/16 07:26:49 AM
#19861   So what did we learn from MNKD ? TREND1 10/15/16 06:11:34 PM
#19860   MNKD closes at all time low of 0.50 TREND1 10/15/16 01:36:25 PM
#19859   Weak weak to ask: Now every week the WHS 10/15/16 08:34:54 AM
#19858 Number of Doctors: 123 WHS 10/15/16 04:35:37 AM
#19857   Anyone in California can tell me what time tyfoidhana 10/14/16 08:38:57 PM
#19856   Are you in Cali tyfoidhana 10/14/16 08:37:49 PM
#19855   Chart Source - Spencer Osborne TREND1 10/14/16 04:56:50 PM
#19854   Buying all the shares i can to keep kugel 10/14/16 03:40:41 PM
#19853   WOW, looks like this company and POS management leslunier 10/14/16 03:37:41 PM
#19852   Bring it on down girls got some money kugel 10/14/16 01:40:34 PM
#19851   Got out a dollar.... Wow where's the bottom? Brentpdc 10/13/16 04:20:37 PM
#19850   MY system had a sell TREND1 10/13/16 03:20:42 PM
#19848   Not sure if this has been posted here, F1ash 10/11/16 07:28:57 PM
#19847   Well stated! Mahalo for your post. I Denise Chanterelle 10/10/16 12:20:08 PM
#19846   Words from a wise man. kugel 10/10/16 08:57:21 AM
#19845   They are on the market now.. It will BUFCARP 10/09/16 07:45:07 PM
#19844   It's going to take gobs of money. Hugodrax 10/09/16 10:23:02 AM
#19843   I'm not going to try and defend the Aloha96707 10/09/16 10:09:57 AM
#19842   maddogismyname FROM SA TREND1 10/08/16 01:16:17 PM